Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most evaluated risk and contraindication statements are supported by the provided PREMARIN label excerpts, but there is a clear contradiction regarding invasive breast cancer risk with estrogen-alone therapy.
Category Scores
Accurate Statements
PREMARIN increases the risk of endometrial cancer when used as unopposed estrogen in women with a uterus.
Label 5.2: “An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus.”
Adding a progestin to postmenopausal estrogen therapy reduces the risk of endometrial hyperplasia (a precursor to endometrial cancer).
Label 5.2: “Adding a progestin … has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.”; Label 2: progestin should be considered to reduce endometrial cancer risk.
An increased risk of stroke and DVT has been reported with estrogen-alone therapy.
Label 5.1: “An increased risk of stroke and DVT has been reported with estrogen-alone therapy.”
An increased risk of PE, DVT, stroke, and MI has been reported with estrogen plus progestin therapy.
Label 5.1: “An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy.”
Estrogen plus progestin therapy is associated with an increased risk of invasive breast cancer (CE plus MPA).
Label 5.2: “After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer…”
PREMARIN is contraindicated with active DVT/PE or a history of these conditions.
Label 4: “Active DVT, PE, or a history of these conditions”
PREMARIN is contraindicated in individuals with breast cancer or a history of breast cancer.
Label 4: “Breast cancer or a history of breast cancer”
WHIMS: PREMARIN (estrogen-alone) is associated with an increased risk of probable dementia.
Label 5.3: “reported an increased risk of developing probable dementia … relative to placebo.”; Label 14.6: “relative risk … 1.49”
WHIMS: PREMARIN (estrogen plus progestin) is associated with an increased risk of probable dementia.
Label 5.3 and 14.6: includes increased risk and relative risk values (e.g., 2.05, pooled overall 1.76).
Unsupported Statements
No additional unsupported (not label-supported) statements were identified in the provided AI-generated evaluations beyond the breast-cancer contradiction noted.
All other evaluated claims were supported by the supplied label excerpts.
Contradictions
High
AI Statement
PREMARIN (estrogen-alone) is associated with an increased risk of invasive breast cancer.
Label Reference
Label 5.2 (Breast Cancer): “In the WHI estrogen-alone substudy… daily CE (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer …”
Important Omissions
No label-grounded statement was provided regarding the boxed warning content itself (beyond referencing reduced endometrial cancer risk with progestin).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
A major contradiction was identified: the AI asserts increased invasive breast cancer risk with estrogen-alone therapy, while the label excerpt states estrogen-alone was not associated with increased invasive breast cancer risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Breast cancer risk claim for estrogen-alone therapy conflicts with label text (label says not associated with increased invasive breast cancer risk).
Suggested Improvement
Remove or revise the estrogen-alone invasive breast cancer risk claim; align it with the label statement that estrogen-alone (CE 0.625 mg) was not associated with increased invasive breast cancer risk, while keeping the increased-risk claim for estrogen plus progestin.